Abstract Body

Background: Methamphetamine (METH) is a widely used recreational drug among HIV-infected men who have sex with men (MSM). Its use is associated with worse health outcomes in HIV-infected individuals. Here we investigated the effect of METH-use on immune function and virus shedding in semen.

Methods: Paired PBMC and semen samples were collected from our in vivo cohort of chronically HIV-infected MSM on suppressive ART (n=50, of whom 16 self-reported METH-use). PBMC were analyzed for markers of immune activation (CD38, HLA-DR and CD45RA), proliferation (Ki67) and exhaustion (PD-1) by flow cytometry. Seminal levels of cytomegalovirus (CMV) and HIV were quantified by real-time PCR. Ex vivo studies were performed on 19 HIV-infected individuals from a treated, but not uniformly suppressed cohort who tested positive for METH by urine toxicology (UTox+) and 19 HIV-infected UTox negative controls (matched for viral load and CD4 T-cell counts). PBMC proliferative responses to mitogen PHA and to CMV, candida, Mycobacterium tuberculosis, toxoplasma and HIV antigens were assayed in triplicate after 7 days of culture. T-cell proliferation was measured by [3H]-thymidine incorporation; stimulation index was calculated as a ratio of the mean counts per minute (cpm) for each stimulus divided by the mean cpm of unstimulated controls. Mann-Whitney and Fisher exact tests were used for continuous and dichotomous data comparisons, respectively.

Results: METH-users had significantly higher CD4 and CD8 T-cell proliferation levels (Ki67+, p<0.005 for both), CD4 T-cell activation (CD45RA–CD38+, p=0.005) and CD4-T cell exhaustion (PD-1+, p=0.0004) compared to non-METH-users. In addition, the proportion of CMV or HIV shedding in METH-users was higher than in non-METH users (75% vs 26% [p=0.002] and 19% vs 3% [p=0.09], respectively). Ex vivo responses of the acute METH UTox+ patients confirmed higher spontaneous PBMC proliferation compared to controls (p<0.05). However, METH UTox+ subjects had significantly reduced proliferation to PHA (p<0.0005) and pathogen antigens (all p<0.04) compared to UTox–.

Conclusions: Our findings suggest that METH-use may activate and exhaust the immune system. Furthermore, METH might reduce the immune response to reactivating or invading pathogens leading to a loss of control of CMV and HIV replication, as suggested by an increase in CMV and HIV seminal shedding in the genital tract. Future studies should consider METH-use as a potential modulator of T-cell responses.